Role of soluble Fas ligand in autoimmune diseases

doi:10.3748/wjg.v10.i21.3151

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 10, Issue 21

This Article

Citation of this article

Corresponding Author of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Number of Hits and Downloads for This Article

Total Article Views (2811)

All Articles published online

The chart showing PDF series, HTML series, Figures (1-8) series, Tables (1-1) series.

Item

Count

PDF

218

HTML

2314

Figures (1-8)

133

Tables (1-1)

146

Sum=2811

Nov 1, 2004 (publication date) through Jul 31, 2024

Times Cited of This Article

Times Cited (19)

Journal Information of This Article

Publication Name

World Journal of Gastroenterology

ISSN

1007-9327

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Basic Research

World J Gastroenterol. Nov 1, 2004; 10(21): 3151-3156
Published online Nov 1, 2004. doi: 10.3748/wjg.v10.i21.3151

Full Size Figure Download Figure

Figure 6 Levels of soluble FasL in serum from patients with different diseases. Cont: Serum from healthy individuals; IDDM: Serum from patients with IDDM; SLE: Serum from IDDM; RAa: Serum from RA patients with activated stage; Ca-ga: Serum from patients with gastric cancer; Leuk: Serum from patients with leukemia; Shadow bar: Serum level detected by commer-cial sFasL kit. Open bar: Serum level detected by anti-sFasL antibody.

Citation: Li NL, Nie H, Yu QW, Zhang JY, Ma AL, Shen BH, Wang L, Bai J, Chen XH, Zhou T, Zhang DQ. Role of soluble Fas ligand in autoimmune diseases. World J Gastroenterol 2004; 10(21): 3151-3156
URL: https://www.wjgnet.com/1007-9327/full/v10/i21/3151.htm
DOI: https://dx.doi.org/10.3748/wjg.v10.i21.3151